SFM
ELVN icon

Sphera Funds Management’s Enliven Therapeutics ELVN Stock Holding History

Sphera Funds Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72M Sell
112,765
-40,500
-26% -$1.72M 0.75% 45
2026
Q1 		$6.01M Sell
153,265
-73,500
-32% -$2.04M 0.95% 37
2025
Q4 		$3.49M Buy
226,765
+60,000
+36% +$1.2M 0.68% 55
2025
Q3 		$3.41M Buy
166,765
+38,250
+30% +$771K 0.72% 46
2025
Q2 		$2.58M Buy
128,515
+16,772
+15% +$318K 0.61% 60
2025
Q1 		$2.2M Buy
+111,743
New +$2.4M 0.51% 62

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Sphera Funds Management's ELVN Position: Q2 2026 in Review

Sphera Funds Management reduced its Enliven Therapeutics (ELVN) stake by 26% in Q2 2026, selling an estimated $1.72M and leaving 112,765 shares worth $5.72M. The position accounts for 0.75% of the portfolio, ranked #45.

Sphera Funds Management first reported a position in ELVN in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.01M in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Sphera Funds Management held 112,765 shares of Enliven Therapeutics worth $5.72M as of Q2 2026.
  • Sphera Funds Management sold 40,500 Enliven Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Enliven Therapeutics made up 0.75% of Sphera Funds Management's portfolio in Q2 2026, its #45 holding.
  • Sphera Funds Management first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Sphera Funds Management's Enliven Therapeutics position peaked at $6.01M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.